Current use of transjugular intrahepatic portosystemic shunts

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The principal indication for transjugular intrahepatic portosystemic shunts (TIPS) continues to be rescue therapy for variceal hemorrhage that cannot be controlled by endoscopic or medical therapy. TIPS provide no survival advantage in prevention of rebleeding or refractory ascites. The indications for TIPS continue to expand, however, especially for Budd-Chiari syndrome and hydrothorax. Other more novel indications include bleeding portal hypertensive gastropathy or ectopic varices, Budd-Chiari syndrome, veno-occlusive disease, hepatorenal syndrome, hepatopulmonary syndrome, hepatocellular carcinoma, and polycystic liver disease. Great strides have been made recently in models to predict mortality and complications following TIPS placement. Graft stents hold promise based on early studies. Finally, complications are common and may be life threatening.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalCurrent gastroenterology reports
Volume5
Issue number1
DOIs
StatePublished - Feb 2003

Fingerprint

Transjugular Intrahepatic Portasystemic Shunt
Budd-Chiari Syndrome
Hepatopulmonary Syndrome
Hydrothorax
Hepatorenal Syndrome
Hemorrhage
Varicose Veins
Ascites
Stents
Hepatocellular Carcinoma
Transplants
Mortality
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current use of transjugular intrahepatic portosystemic shunts. / McCashland, Timothy M.

In: Current gastroenterology reports, Vol. 5, No. 1, 02.2003, p. 31-38.

Research output: Contribution to journalReview article

@article{fce31f9fd3d24d8c9700177b1046a0ba,
title = "Current use of transjugular intrahepatic portosystemic shunts",
abstract = "The principal indication for transjugular intrahepatic portosystemic shunts (TIPS) continues to be rescue therapy for variceal hemorrhage that cannot be controlled by endoscopic or medical therapy. TIPS provide no survival advantage in prevention of rebleeding or refractory ascites. The indications for TIPS continue to expand, however, especially for Budd-Chiari syndrome and hydrothorax. Other more novel indications include bleeding portal hypertensive gastropathy or ectopic varices, Budd-Chiari syndrome, veno-occlusive disease, hepatorenal syndrome, hepatopulmonary syndrome, hepatocellular carcinoma, and polycystic liver disease. Great strides have been made recently in models to predict mortality and complications following TIPS placement. Graft stents hold promise based on early studies. Finally, complications are common and may be life threatening.",
author = "McCashland, {Timothy M}",
year = "2003",
month = "2",
doi = "10.1007/s11894-003-0007-9",
language = "English (US)",
volume = "5",
pages = "31--38",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Current use of transjugular intrahepatic portosystemic shunts

AU - McCashland, Timothy M

PY - 2003/2

Y1 - 2003/2

N2 - The principal indication for transjugular intrahepatic portosystemic shunts (TIPS) continues to be rescue therapy for variceal hemorrhage that cannot be controlled by endoscopic or medical therapy. TIPS provide no survival advantage in prevention of rebleeding or refractory ascites. The indications for TIPS continue to expand, however, especially for Budd-Chiari syndrome and hydrothorax. Other more novel indications include bleeding portal hypertensive gastropathy or ectopic varices, Budd-Chiari syndrome, veno-occlusive disease, hepatorenal syndrome, hepatopulmonary syndrome, hepatocellular carcinoma, and polycystic liver disease. Great strides have been made recently in models to predict mortality and complications following TIPS placement. Graft stents hold promise based on early studies. Finally, complications are common and may be life threatening.

AB - The principal indication for transjugular intrahepatic portosystemic shunts (TIPS) continues to be rescue therapy for variceal hemorrhage that cannot be controlled by endoscopic or medical therapy. TIPS provide no survival advantage in prevention of rebleeding or refractory ascites. The indications for TIPS continue to expand, however, especially for Budd-Chiari syndrome and hydrothorax. Other more novel indications include bleeding portal hypertensive gastropathy or ectopic varices, Budd-Chiari syndrome, veno-occlusive disease, hepatorenal syndrome, hepatopulmonary syndrome, hepatocellular carcinoma, and polycystic liver disease. Great strides have been made recently in models to predict mortality and complications following TIPS placement. Graft stents hold promise based on early studies. Finally, complications are common and may be life threatening.

UR - http://www.scopus.com/inward/record.url?scp=0037607655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037607655&partnerID=8YFLogxK

U2 - 10.1007/s11894-003-0007-9

DO - 10.1007/s11894-003-0007-9

M3 - Review article

C2 - 12530946

AN - SCOPUS:0037607655

VL - 5

SP - 31

EP - 38

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 1

ER -